Marien Hospital Herne

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation3 trials
• Bladder cancer3 trials
• Chronic lymphocytic leukaemia2 trials
• Acute myeloid leukaemia1 trial
• Colorectal cancer1 trial
• Gastric and oesophageal cancer1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 38 trials
• Phase 21 trial

Status

• Not yet recruiting4 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Completed2 trials

Lead sponsor

• Hoffmann-La Roche2 trials
• Asklepios proresearch1 trial
• Astellas Pharma Global Development, Inc.1 trial
• German CLL Study Group1 trial
• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1 trial
• and 5 more

Running trials

• Not yet recruiting

  Single-Shot Versus Focal Dual-Energy Pulsed Field-Based Ablation for Atrial Fibrillation

  NCT07783919· Marien Hospital Herne· Source

  Contact: Dimitrios Bismpos

• Recruiting

  PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study

  NCT07621003· Asklepios proresearch· Source

  Contact: Christian Ukena, MD

• Recruiting

  Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  NCT07566156· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  NCT06534983· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Colchicine After Electrocardioversion for Atrial Fibrillation

  NCT05890664· Phase 3· University Hospital, Basel, Switzerland· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· University of Ulm· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· German CLL Study Group· Source

• Recruiting

  HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

  NCT04447352· Phase 3· Krankenhaus Nordwest· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Bladder cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Myelodysplastic syndromes1 recruiting

Closed trials

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source